TACTI-004 to be discontinued following futility analysis
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The trial was evaluating eftilagimod alfa in patients with first line non-small cell lung cancer. Enrolment in the study will be halted, and the company will wind down the study while ensuring patient follow-up and site closure. Immutep plans to conduct a comprehensive review of the data to determine next steps for the program.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Immutep
- Suspension from Quotation
- Trading Halt
- Half Yearly Report and Accounts
- Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
- Immutep Achieves 50% Enrolment in Global TACTI-004-1L NSCLC
Later from Immutep
- TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
- Update on Phase I Study of IMP761 for Autoimmune Diseases
- Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases
- Immutep receives FDA ODD for Efti in Soft Tissue Sarcoma
- Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep